GTC Biotherapeutics (fka GTCB)

[croumagnon]

With regard to the 17th patient, I presume that even if in the worse case scenario that particular patient developed Symptomatic DVT, GTCB will still have met the hurdle of its non-inferiority primary endpoint otherwise they would not have claimed that they had done so already...

Am I correct in my assumption?